Arbutus Biopharma earnings beat, Revenue misses in Q3

  • Investing.com
Arbutus Biopharma earnings beat, Revenue misses in Q3

Investing.com - Arbutus Biopharma reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.

Arbutus Biopharma announced earnings per share of $-0.120 on revenue of $5.95M. Analysts polled by Investing.com anticipated EPS of $-0.140 on revenue of $6.64M.

Arbutus Biopharma shares are down 16.73% from the beginning of the year and are trading at $2.390 , down-from-52-week-high.

Arbutus Biopharma shares lost 2.85% in pre-market trade the report.

Arbutus Biopharma follows other major Healthcare sector earnings this month

Arbutus Biopharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.

J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles